Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13434056 | 0.88 | PTPN1 (0.51) | MEN1KMT2AKDM4ETDP1CYP3A4 | |
| SCHEMBL30511914 | 0.88 | PTPN1 (0.51) | MEN1KMT2AKDM4ETDP1CYP3A4 | |
| SCHEMBL13609760 | 0.86 | MEN1 (0.50) | MEN1KMT2AKDM4ETDP1CYP3A4 | |
| SCHEMBL2308927 | 0.85 | FABP5 (0.53) | MEN1KMT2AKDM4EFABP5SMN1; SMN2 | |
| SCHEMBL19475149 | 0.83 | FABP5 (0.49) | MEN1KMT2AKDM4EFABP5SMN1; SMN2 | |
| SCHEMBL16005654 | 0.83 | FABP5 (0.49) | MEN1KMT2AKDM4EFABP5SMN1; SMN2 | |
| SCHEMBL18674157 | 0.83 | FABP5 (0.49) | MEN1KMT2AKDM4EFABP5SMN1; SMN2 | |
| SCHEMBL28169221 | 0.83 | FABP5 (0.49) | MEN1KMT2AFABP5SMN1; SMN2MAPT | |
| SCHEMBL19808818 | 0.81 | KDM4E (0.51) | MEN1KMT2AKDM4ETDP1CYP3A4 | |
| SCHEMBL6688920 | 0.80 | HTT (0.56) | MEN1KMT2AKDM4ETDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2874987-B1 | alpha-AND gamma-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2020-03-25 | — | — | EP | disclosed |
| CN-105884752-B | And ring class gyrase and topoisomerase I V inhibitor | 山东轩竹医药科技有限公司 | 2018-08-31 | — | — | CN | disclosed |
| US-20170216241-A1 | ALPHA- AND GAMMA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2017-08-03 | — | — | US | disclosed |
| US-9604904-B2 | Alpha- and gamma-truxillic acid derivatives and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2017-03-28 | — | — | US | disclosed |
| CN-105884752-A | Cyclic gyrase and topoisomerase IV inhibitor | 山东轩竹医药科技有限公司 | 2016-08-24 | — | — | CN | disclosed |
| EP-2121638-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20160074853-A1 | LIGAND, NICKEL COMPLEX COMPRISING THE LIGAND, AND REACTION USING THE NICKEL COMPLEX | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2016-03-17 | — | — | US | disclosed |
| CN-104583212-A | Pyrimidinone derivatives as antimalarial agents | SANOFI SA | 2015-04-29 | — | — | CN | disclosed |
| WO-2014015276-A1 | α-AND γ-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2014-01-23 | — | — | WO | disclosed |
| US-20100286192-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ANTHONY NEVILLE J | 2010-11-11 | — | — | US | disclosed |
| US-20080275097-A1 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME LLC | 2008-11-06 | — | — | US | disclosed |
| WO-2008076225-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1405848-B1 | TETRAHYDROQUINOLINE DERIVATIVE COMPOUND AND DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2008-05-07 | — | — | EP | disclosed |
| EP-1405848-B1 | TETRAHYDROQUINOLINE DERIVATIVE COMPOUND AND DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2008-05-07 | — | — | EP | disclosed |
| US-6924295-B2 | Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| CN-1608061-A | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2005-04-20 | — | — | CN | disclosed |
| US-20040171835-A1 | Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-09-02 | — | — | US | disclosed |
| EP-1405848-A1 | TETRAHYDROQUINOLINE DERIVATIVE COMPOUND AND DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| CN-1059442-C | Use of 1, 2-bridged 1, 4-dihydropyridines as medicaments | BAYER AG (DE) | 2000-12-13 | — | — | CN | disclosed |
| CN-1133841-A | Use of 1, 2-bridged 1, 4-dihydropyridines as medicaments | BAYER AG (DE) | 1996-10-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275097-A1 | Non-nucleoside reverse transcriptase inhibitors | RNGTT, RRM2B, RRM2 | MEN1 4555/4885KMT2A 576/4885KDM4E 302/4885 |
| US-20160074853-A1 | LIGAND, NICKEL COMPLEX COMPRISING THE LIGAND, AND REACTION USING THE NICKEL COMPLEX | NISCH, DDT, TEC | MEN1 1615/4885KMT2A 2140/4885KDM4E 2004/4885 |
| US-20100286192-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | RNGTT, RRM2B, RRM2 | MEN1 4555/4885KMT2A 576/4885KDM4E 302/4885 |
| US-20040171835-A1 | Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient | SREBF1, NR1H2, NR1H3 | MEN1 4353/4885KMT2A 765/4885KDM4E 1454/4885 |
| US-20170216241-A1 | ALPHA- AND GAMMA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | FABP1, FABP2, FABP7 | MEN1 4872/4885KMT2A 4598/4885KDM4E 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.